
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Clinical site visits by patients may not be possible as healthcare providers focus their efforts on patients who require urgent care as a result of the COVID-19 pandemic. ERT has announced a cardiac safety solution that helps biopharmaceutical researchers continue important clinical trials during current global ‘stay home’ mandates. The solution enables clinician-administered ECG readings, using ERT’s provisioned, FDA-cleared devices or other investigative site-owned equipment.
To learn more, click






